CAR T targeting CD44E splicing variant shows potential for HCC treatment

AI Briefing

• – Researchers identified CD44E, a unique alternative splicing variant of CD44, which is highly expressed in HCC tumors but limited in normal tissues.
• – The CD44E variant is a potential target for HCC treatment.
• – Further studies are needed to confirm the clinical potential of CD44E as a therapeutic target.